Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Share:
Related JAZZ
'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market
Jazz Pharma Gives Shorts A Wake-Up Call After JZP-110 Study Results
Discussing The Evolving AML Landscape With A Key Opinion Leader (Seeking Alpha)

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Feb 2017Evercore ISI GroupInitiates Coverage OnBuy
Dec 2016Cantor FitzgeraldInitiates Coverage OnOverweight
Aug 2016Janney CapitalInitiates Coverage onNeutral

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!